> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Twist Bioscience Sales Rise 28% As Quarterly Adjusted EBITDA Turns Positive
- URL: https://www.bullished.co/twist-bioscience-sales-rise-28-as-quarterly-adjusted-ebitda-turns-positive-4676c453/
- Published: 2026-11-12T12:36:06.000Z
- Updated: 2026-11-12T12:36:06.000Z
- Description: Its fiscal 2027 sales forecast assumes $100 million from AI drug discovery, alongside a $75 million capital-spending plan.
- Author: Matteo Parrino
- Tags: SEC Filings, TWST, Industry: Healthcare

[Twist Bioscience](https://www.bullished.co/tag/twst/), which makes custom DNA and tools for genetic sequencing and antibody discovery, grew fourth-quarter sales 28% to [$126.6 million](https://www.sec.gov/Archives/edgar/data/0001581280/000158128026000053/twist-20261112.htm?ref=bullished.co) from $99.0 million a year earlier. Its earnings release accompanying Thursday's SEC filing also showed positive quarterly adjusted EBITDA, although the company remained loss-making under standard accounting.

## DNA And Proteins Lead Growth

Quarterly adjusted EBITDA reached [$2.2 million](https://www.sec.gov/Archives/edgar/data/0001581280/000158128026000053/twst-2026930xex991.htm?ref=bullished.co), against negative $7.8 million a year earlier. That measure removes interest, taxes, depreciation and selected expenses, including stock-based pay, which totaled $19.5 million in the quarter.

The net loss narrowed to $20.6 million, or $0.32 per share, from $27.1 million, or $0.45 per share. Gross margin rose to 53.1% from 51.3%, while quarterly research spending held at $17.0 million and selling and administrative expenses increased to $74.7 million from $63.8 million.

DNA synthesis and protein-solutions revenue rose 33% to $61.0 million. Sequencing-applications sales increased 24% to $65.7 million. Against the third quarter, those businesses grew 8% and 6%, respectively; Twist called this its 15th consecutive quarter of revenue growth from the preceding quarter.

## A Wider Annual Accounting Loss

Fiscal 2026 revenue rose 22% to $459.4 million from $376.6 million. DNA synthesis and protein solutions contributed $221.9 million, up 31.7%, while sequencing applications generated $237.5 million, up 14.1%.

Annual adjusted EBITDA improved to negative $35.9 million from negative $46.9 million. But the annual net loss widened to $130.2 million, or $2.08 per share, from $77.7 million, or $1.30 per share. The fiscal 2025 results included a $48.8 million business-sale gain; fiscal 2026 included $7.2 million in litigation settlement costs, net of recoveries.

Full-year gross margin increased to 52.4% from 50.7%. Research spending fell to $71.8 million from $80.3 million, while selling and administrative expenses rose to $301.2 million from $247.0 million.

Twist uses a silicon-chip platform to produce custom genes and other DNA products for researchers and commercial customers. It shipped approximately 1.3 million genes in fiscal 2026, versus approximately 938,000 in fiscal 2025, and supplied approximately 4,100 customers, versus approximately 3,800.

## The $100 Million AI Assumption

Twist expects fiscal 2027 revenue of approximately [$550 million to $560 million](https://www.sec.gov/Archives/edgar/data/0001581280/000158128026000053/twst-2026930xex991.htm?ref=bullished.co), about 21% growth at the midpoint. The forecast assumes $100 million from AI drug discovery and continued quarter-to-quarter growth in both businesses.

The AI work includes an assignment disclosed in August: Anthropic chose Twist as an independent evaluator to [produce and test](https://www.sec.gov/Archives/edgar/data/0001581280/000158128026000050/twist-20260818.htm?ref=bullished.co) AI-designed proteins against 15 targets. Twist's role involved making the proteins at scale and testing whether they bound to those targets.

CEO and co-founder Emily M. Leproust said Twist is "investing in capacity, automation and new products that enable customers to do more with Twist."

Management expects positive adjusted EBITDA and gross margin of approximately 52.5% to 53% for fiscal 2027\. It plans approximately $75 million in capital spending under a two-year investment plan, excluding tenant improvements funded by landlords. Twist ended September with approximately $582 million in cash, cash equivalents and short-term investments, having raised approximately $425 million net through an equity offering and market sales.

For the first quarter of fiscal 2027, Twist expects approximately $130 million to $132 million in revenue—about 26% growth from a year earlier at the midpoint.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Twist Bioscience Corp (TWST)](https://www.sec.gov/Archives/edgar/data/0001581280/000158128026000053/twist-20261112.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit twst-2026930xex991.htm — Twist Bioscience Corp 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001581280/000158128026000053/twst-2026930xex991.htm?ref=bullished.co) — SEC EDGAR
- [8-K filed 2026-08-19 — Twist Bioscience Corp (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001581280/000158128026000050/twist-20260818.htm?ref=bullished.co) — SEC EDGAR

### More on Twist Bioscience

- [State Street Holds 4.6% Of Twist Bioscience Without Seeking To Influence Control](https://www.bullished.co/state-street-holds-4-6-of-twist-bioscience-without-seeking-to-influence-control-6fdf48bc/)

[All Twist Bioscience (TWST) coverage →](https://www.bullished.co/tag/twst/)